A gene expression predictor of response to EGFR-targeted therapy stratifies progression-free survival to cetuximab in KRAS wild-type metastatic colorectal cancer

被引：0
|
作者：
Justin M Balko
Esther P Black
机构：
[1] College of Pharmacy,Department of Pharmaceutical Sciences
[2] University of Kentucky,undefined
来源：
BMC Cancer | / 9卷
关键词：
Progression Free Survival; Cetuximab; Erlotinib; KRAS Mutation; Lung Cancer Cell Line;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Overexpression of MET is a new predictive marker for anti-EGFR therapy in metastatic colorectal cancer with wild-type KRAS
    Tomokazu Kishiki
    Hiroaki Ohnishi
    Tadahiko Masaki
    Kouki Ohtsuka
    Yasuo Ohkura
    Jyunji Furuse
    Takashi Watanabe
    Masanori Sugiyama
    Cancer Chemotherapy and Pharmacology, 2014, 73 : 749 - 757
  • [42] EGFR Protein Expression of KRAS Wild-Type Colorectal Cancer: Predictive Value of the Sidedness for Efficacy of Anti-EGFR Therapy
    Uhlyarik, A.
    Piurko, V
    Vizkeleti, L.
    Papai, Zs
    Raso, E.
    Lahm, E.
    Kiss, E.
    Sikter, M.
    Vachaja, J.
    Kenessey, I
    Timar, Jozsef
    PATHOLOGY & ONCOLOGY RESEARCH, 2020, 26 (03) : 1429 - 1434
  • [43] Overexpression of MET is a new predictive marker for anti-EGFR therapy in metastatic colorectal cancer with wild-type KRAS
    Kishiki, Tomokazu
    Ohnishi, Hiroaki
    Masaki, Tadahiko
    Ohtsuka, Kouki
    Ohkura, Yasuo
    Furuse, Jyunji
    Watanabe, Takashi
    Sugiyama, Masanori
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (04) : 749 - 757
  • [44] Preclinical update on targeting KRAS wild-type colorectal cancer with an EGFR-targeted monoclonal tri-body mixture, MM-151
    Carey, Shawn P.
    Wang, Hongfang
    Handly, Erika
    Ahlstedt, Brittany
    Gaddy, Daniel
    Kearns, Jeffrey D.
    Finn, Greg
    Schoeberl, Birgit
    Nering, Rachel
    CANCER RESEARCH, 2017, 77
  • [45] Sequential cetuximab/bevacizumab therapy is associated with improved outcomes in patients with wild-type KRAS exon 2 metastatic colorectal cancer
    Hsu, Hung-Chih
    Liu, Yu-Chun
    Wang, Chuang-Wei
    Chou, Wen-Chi
    Hsu, Yu-Jen
    Chiang, Jy-Ming
    Lin, Yung-Chang
    Yang, Tsai-Sheng
    CANCER MEDICINE, 2019, 8 (07): : 3437 - 3446
  • [46] The impact of co-expression of wild-type EGFR and its ligands determined by immunohistochemistry for response to treatment with cetuximab in patients with metastatic colorectal cancer
    Khelwatty, Said
    Essapen, Sharadah
    Bagwan, Izhar
    Green, Margaret
    Seddon, Alan
    Modjtahedi, Helmout
    ONCOTARGET, 2017, 8 (05) : 7666 - 7677
  • [47] Panitumumab monotherapy compared with cetuximab and irinotecan combination therapy in patients with previously treated KRAS wild-type metastatic colorectal cancer
    Kennecke, H.
    Chen, L.
    Blanke, C. D.
    Cheung, W. Y.
    Schaff, K.
    Speers, C.
    CURRENT ONCOLOGY, 2013, 20 (06) : 326 - 332
  • [48] CLINICAL VALIDATION OF A 26-GENE SIGNATURE PREDICTING RESPONSE TO CETUXIMAB IN WILD TYPE KRAS METASTATIC COLORECTAL CANCER
    Vuaroqueaux, V.
    Korrat, A.
    Foucault, F.
    Beckers, T.
    Fiebig, H.
    ANNALS OF ONCOLOGY, 2010, 21 : 70 - 70
  • [49] Circulating tumor cells as predictive marker in panitumumab after progression of cetuximab in Japanese patients with KRAS wild-type metastatic colorectal cancer
    Ohhara, Yoshihito
    Matsusaka, Satoshi
    Shinozaki, Eiji
    Suenaga, Mitsukuni
    Mizunuma, Nobuyuki
    Hatake, Kiyohiko
    Yamaguchi, Toshiharu
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [50] EGFR Fluorescence In situ Hybridization Pattern of Chromosome 7 Disomy Predicts Resistance to Cetuximab in KRAS Wild-type Metastatic Colorectal Cancer Patients
    Li, Yu-Hong
    Wang, Fang
    Shen, Lin
    Deng, Yan-Ming
    Shao, Qiong
    Feng, Fen
    An, Xin
    Wang, Feng-Hua
    Wang, Zhi-Qiang
    Xu, Rui-Hua
    Shao, Jian-Yong
    CLINICAL CANCER RESEARCH, 2011, 17 (02) : 382 - 390
12345